Insilico Medicine � PHD1/2 Inhibitor (Anemia of CKD treatment)

This drug is a small molecule inhibitor of PHD1/2 designed to treat anemia of chronic kidney disease (CKD). PHD1/2 inhibition can upregulate the expression of several iron metabolism genes and address both impaired EPO production and functional iron deficiency, common in anemia of CKD. The drug aims to enhance EPO secretion, stimulating red blood cell production and potentially ameliorating anemia.